TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CandeSpartan Study. Candesartan Spanish Response-prediction and Tolerability Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~Diagnosis of migraine (episodic or chronic) according to the International Classification of headache Disorders (ICHD), 3rd version, criteria10.~Being treated with Candesartan under the criteria of the physician and according to local guidelines.~Age \>18 years. More than 4 days of headache per month in the preceding 3 months. More than 1 year of migraine evolution. Beginning of migraine before the age of 50. Ability to provide informed consent.~Exclusion criteria:~Previous failure of three or more preventive drugs in accordance with the definition provided below.~Concomitant use of another preventive drug or use of it in less than 5-half lives of the drug.~History of another active primary headache with a periodicity considered frequent according to the International Classification of Headache disorders, that is, more than 10 days per month at the time of screening or the basal period.~Continuous or daily headache in the month prior to inclusion in the study. Pregnancy or breastfeeding. Any relevant cardiovascular conditions. Kidney diseases. Hyperkaliemia. Use of another concomitant preventive. Previous use of candesartan. Current use of another Angiotensin Conversing Enzime Inhibitor or Angiotensin-II receptor antagonist.~Alcoholism or drug use.~Concomitant treatment:~The study will not interfere in the current practice, participants will receive the candesartan in the same manner and intensity if they were not enrolled in the study.~Patients will be allowed to use their usual symptomatic treatment as usual. The number of days of symptomatic treatment and the number of use of triptans will be reflected.~The concomitant drugs with potential use as a preventive according to National Clinical Practice guidelines (gabapentin, pregabalin, tricyclic antidepressants, duloxetine, valproic acid, phenytoin, lamotrigine, topiramate, botulinum toxin, anti-CGRP antibodies, beta-blockers, lisinopril) will not be permitted.~Treatment failure shall be defined as insufficient efficacy at a sufficient dose and for an adequate duration or withdrawal due to adverse effects of a drug present in the national headache guidelines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Migraine patients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Recent cryptogenic symptomatic transient ischemic attack (TIA) or cryptogenic ischemic stroke.~Exclusion Criteria:~1. Known etiology of TIA or stroke.~2. Untreated hyperthyroidism.~3. Myocardial infarction less than 1 month prior to stroke or TIA.~4. Coronary bypass grafting less than 1 month prior to stroke or TIA.~5. Valvular disease requiring immediate surgical intervention.~6. History of AF or atrial flutter.~7. Patent Foramen Ovale (PFO) and PFO is or was an indication to start oral anticoagulation (OAC).~8. Permanent indication for OAC at enrollment.~9. Permanent contra-indication for OAC.~10. Included in another clinical trial.~11. Life expectancy less than 1 year.~12. Pregnant.~13. Indicated for Implantable Pulse Generator (IPG), Implantable Cardioverter-Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT) or an implantable hemodynamic monitoring system.~14. Not fit, unable or unwilling to follow the required procedures of the protocol.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous Monitoring (Type: ACTIVE_COMPARATOR): Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
- Control Arm (Type: NO_INTERVENTION): Follow-up at the same frequency, but with no Insertable Cardiac Monitor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to any study-mandated procedure (Visit 1).~* Having completed the DB study treatment and the run-out period of ID-078A301 (NCT03545191) or ID-078A302 (NCT03575104).~* For woman of childbearing potential, the following is required:~  * Negative urine pregnancy test (EOT of ID-078A301 or ID-078A302 studies)~ * Agreement to use the contraception scheme as required by the protocol from Visit 1 up to at least 30 days after EODBT.~Exclusion Criteria:~* Unstable medical condition, significant medical disorder or acute illness, C-SSRS©, ECG, hematology or biochemistry test results in ID-078A301 and ID-078A302, which in the opinion of the investigator could affect the subject's safety or interfere with the study assessments (Visit 1).~* For female subjects: lactating or planning to become pregnant during the duration of the study (Visit 1).~* Positive urine drug test (for benzodiazepines, barbiturates, cannabinoids, opiates, amphetamines, or cocaine) or presence of alcohol in exhaled breath as detected by breathalyzer test (EOT of ID-078A301 or ID-078A302 studies if same day as Visit 1 or Visit 1 if within 7 days after EOT).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daridorexant 10 mg (Type: EXPERIMENTAL): Film-coated tablets administered orally, once daily in the evening
- Daridorexant 25 mg (Type: EXPERIMENTAL): Film-coated tablets administered orally, once daily in the evening
- Daridorexant 50 mg (Type: EXPERIMENTAL): Film-coated tablets administered orally, once daily in the evening
- Placebo (Type: PLACEBO_COMPARATOR): Film-coated tablets administered orally, once daily in the evening
- Ex-Placebo Daridorexant 25 mg (Type: EXPERIMENTAL): Film-coated tablets administered orally, once daily in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* triglycerides 150-500 mg/dL~* age 21-65 years~* generally healthy~* body mass index (BMI) 20-39 kg/m2~Exclusion Criteria:~* smoking~* premenopausal (if female)~* use of hormone replacement or oral contraceptives~* use of lipid lowering or blood pressure medication~* hypertension (blood pressure \> 150/95 mm Hg)~* peripheral vascular disease~* heart disease, diabetes, or stroke~* inflammatory disease (e.g. rheumatoid arthritis or Crohn's)~* elevated liver enzymes~* high intake of omega-3 containing foods~* allergy to adhesive or latex~* use of aspirin, anticoagulants, or SSRI

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 4g P-OM3, then 1g P-OM3, then Placebo (Type: EXPERIMENTAL): 4 g/day Dose Prescription Omega-3 acid ethyl esters (P-OM3)capsules(4) for first intervention (8 weeks), followed by 1g/day P-OM3 capsules(4) for 2nd intervention (8 weeks), followed by Placebo corn oil capsules, 4/day, for the 3rd intervention (8 weeks).
- 1g P-OM3, then 4g P-OM3, then Placebo (Type: EXPERIMENTAL): 1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks,followed by 6-wk washout. Placebo capsules for 8-wks.
- Placebo, then 4g P-OM3, then 1g P-OM3 (Type: EXPERIMENTAL): Corn Oil placebo capsules for 8-wks, followed by 6-wk washout. 4g P-OM3 capsules for 8-wks, followed by 6-wk washout. 1g P-OM3 for 8-wks.
- 4g P-OM3, then Placebo, then 1g P-OM3 (Type: EXPERIMENTAL): 4g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 1g capsules for 8 wks.
- 1g P-OM3, then Placebo, then 4g P-OM3 (Type: EXPERIMENTAL): 1g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
- Placebo, then 1g P-OM3, then 4g P-OM3 (Type: EXPERIMENTAL): Corn oil placebo capsules for 8-wks, followed by 6-wk washout.1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults age with established, pathologically confirmed diagnoses of newly diagnosed AML, including de novo and secondary AMLs but excluding newly diagnosed acute progranulocytic leukemia (APL, M3), will be considered eligible for study~* ECOG performance status 0-2~* Patient must be able to give informed consent~* Serum creatinine =\< 2.0 mg/dl~* SGOT and SGPT =\< 5 x upper limit normal (ULN)~* Bilirubin =\< 2 mg/dl~* Disease-specific criteria:~  * Newly diagnosed AML, subtypes M0,1,2,4-7 but excluding M3 (APL), including myelodysplasia (MDS)-related AML (MDS/AML) and treatment-related AML~ * Patients who have received hydroxyurea alone or have received non-cytotoxic therapies previously for MDS (e.g., thalidomide, interferon, cytokines, 5-azacytidine) will be eligible for this trial~Exclusion Criteria:~* Any previous treatment with R115777 or VP-16~* Patients receiving concomitant chemotherapy, radiation therapy or immunotherapy~* Hyperleukocytosis with \>= 30,000 blasts/uL or rapidly rising blast count with projected doubling time of =\< 2 days~* Acute progranulocytic leukemia (APL,M3)~* Active CNS leukemia~* Active, uncontrolled infection; patients with infection under active treatment and controlled with antibiotics are eligible~* Presence of other life-threatening illness~* Patients with mental deficits and/or psychiatric history that preclude them from giving informed consent or from following protocol~* Patients on enzyme-inducing anti-convulsants (e.g., phenytoin, fosphenytoin, phenobarbital, primidone, carbamazepine, oxcarbazepine); patients may be changed to non-enzyme inducing anti-convulsants and stabilized before starting study treatment

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (tipifarnib, etoposide) (Type: EXPERIMENTAL): Patients receive oral tipifarnib twice daily on days 1-14 OR 1-21 and oral etoposide once daily on days 1-3 and 8-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR may receive up to 5 additional courses of therapy beyond documentation of CR.~Cohorts of 3-6 patients receive escalating doses of tipifarnib and etoposide until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 14 additional patients receive treatment at the MTD.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of AML or ALL: CR2 or subsequent complete remission (CR) or CR1 with high-risk features or relapse with \< 10% blasts in BM and no circulating blasts.~2. Clinical diagnosis of CML: in CP1 (Chronic Phase 1) and resistant or intolerant to Gleevec or in CP2 or subsequent CP or in accelerated phase.~3. Clinical diagnosis of HD: induction failure or relapse and sensitive to last chemotherapy course.~4. Clinical diagnosis of NHL induction failure or relapse and sensitive to last chemotherapy course.~5. Clinical diagnosis of MDS with intermediate 2- or high-risk IPSS score.~Exclusion Criteria:~1. Less than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning (except Hydroxyurea).~2. HIV positive.~3. Pregnancy or lactation.~4. Uncontrolled bacterial, fungal or viral infection.~5. Subjects with signs and symptoms of active central nervous system (CNS) disease.~6. Availability of appropriate related and willing stem cell donor, who is HLA-matched at 5 or 6/6 antigens.~7. Prior allogeneic cell transplant.~8. Allergy to bovine or to any product, which may interfere with the treatment.~9. Enrolled in another clinical trial or received an investigational treatment during the last 30 days, unless approved by Sponsor.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- StemEx (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Phase I (closed as of 5/30/02):~  * Histologically confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effective~* Phase II:~  * Histologically confirmed metastatic or unresectable colorectal adenocarcinoma~* Measurable disease or assessable but nonmeasurable disease (including ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonis, inflammatory breast disease, abdominal masses (not followed by CT scan/MRI), or cystic lesions)~  * Disease characterized only by elevated serum tumor marker allowed~* No known brain metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2 OR~* Karnofsky 60-100%~Life expectancy:~* More than 3 months~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm \^3~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~* AST/ALT no greater than 2.5 times upper limit of normal~Renal:~* Creatinine normal OR~* Creatinine clearance at least 60 mL/min~Cardiovascular:~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No ongoing or active infection~* No peripheral neuropathy~* No prior allergic reactions to compounds of similar chemical or biologic composition to gefitinib or other study agents~* No other concurrent uncontrolled illness~* No psychiatric illness or social situation that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior bone marrow or stem cell support with high-dose chemotherapy~* At least 24 hours since prior colony-stimulating growth factors~Chemotherapy:~* See Biologic therapy~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered~* No more than 3 prior chemotherapy regimens~Endocrine therapy:~* At least 2 weeks since prior hormonal therapy except megestrol for anorexia/cachexia~Radiotherapy:~* No prior pelvic or whole abdominal radiotherapy~* At least 4 weeks since other prior radiotherapy and recovered~Surgery:~* At least 4 weeks since prior major surgery (e.g., laparotomy) and recovered~Other:~* At least 4 weeks since prior investigational therapy~* No other concurrent investigational or commercial anticancer agents~* No concurrent combination antiretroviral therapy for HIV-positive patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adipokines in Obese Adolescents With Insulin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obesity defined as Body Mass Index (BMI) ≥ percentile 95~* Tanner stage ≥ 2~* Insulin resistance defined as Basal insulin \> 15 µU/mL or Homeostasis Model Assessment index (HOMA) \> 4.5~* Patients' parents signed written consents when they and their adolescent children agreed to enroll~Exclusion Criteria:~* Glucose intolerance~* Diabetes mellitus (type 1 or 2)~* Anemia (Hb \< 10 g/dL)~* Plasma creatinine \> 1.4 mg/dL~* Abnormal hepatic function~* Any associated Disease (Pulmonary, Infection, Autoimmune Disease)~* History of lactic acidosis

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
- Placebo (Type: PLACEBO_COMPARATOR): Tablet of 500 mg oral placebo every 12 hours for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active acromegaly \[serum GH levels above 2.5 μg/liter and/or above 1 μg/liter after oral glucose tolerance test (OGTT) and abnormal IGF-I values\] with a micro- (\<10 mm max tumor diameter) or macroadenoma (\>10 mm max tumor diameter)~* Patients never treated before~* Patients who do not require immediate surgery because of neurological symptoms and/or emergency conditions~* Patients who signed an informed consent to participate to the study.~Exclusion Criteria:~* Patients already treated before with surgery or radiotherapy or with medical treatment~* Patients with mixed GH-PRL adenomas who require combined somatostatin and dopamine treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Newly diagnosed patients with acromegaly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 20 to 75~* Performance status 0 , 1, or 2 (ECOG)~* Hematopoietic WBC ≥ 4,000/mm\^3 Platelet ≥ 100,000/mm\^3~* Hepatic AST and ALT ≤ 2 times upper limit of normal(ULN) Total bilirubin ≤ 1.2mg/dL~* Renal BUN ≤ 25mg/dL Creatinine ≤ 1.5mg/dL~Exclusion Criteria:~* Prior anticancer treatment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): UFT (uracil, tegafur)
- 2 (Type: OTHER): Surgery alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 18 to 65 years of age (inclusive)~* Diagnosis of RA~* Swollen joint count of ≥6 out of 66 joints and tender joint count of ≥6 out of 68 joints~* Seropositivity based on either a positive rheumatoid factor or anti cyclic citrullinated peptide antibody at screening -OR- known erosive disease based on previous X-ray report or erosions detected on screening hand and foot X-ray~* Baseline CRP level or Westergren erythrocyte sedimentation rate ≥1.2 × upper limit of normal~* Receiving stable therapy with 1 of the following DMARDs: methotrexate, sulfasalazine, leflunomide, anti-malarial drug, or penicillamine~* Palpable 2+ synovitis of the wrist or ≥2 MCPs in the MRI-designated hand~Exclusion Criteria:~* History or presence of a clinically significant medical disorder other than RA that, in the opinion of the investigator and medical monitor, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.~* Inflammatory, rheumatological disorders other than RA, where arthritis may be a prominent feature~* Planned surgery during the study~* History of alcohol or drug abuse, or excessive alcohol consumption~* History of tuberculosis (TB) infection of any kind (pulmonary or extrapulmonary, active or latent), regardless of history of anti-TB treatment.~* Pregnant or nursing an infant or with a life partner who is pregnant, nursing, or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VX-509 100 mg qd Arm (Type: EXPERIMENTAL): None
- VX-509 200 mg qd Arm (Type: EXPERIMENTAL): None
- VX-509 300 mg qd Arm (Type: EXPERIMENTAL): None
- Placebo Arm (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete